After IPO, Durham's Dova could launch drug as early as next year

Following its initial public offering – which yielded net proceeds of roughly $78.8 million, after underwriting discounts and offering expenses – Durham-based Dova Pharmaceuticals (Nasdaq: DOVA) could launch its platelet deficiency drug as early as next year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.